Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD
| العنوان: | Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD |
|---|---|
| المؤلفون: | Nicolas Hanset, Karine Dahan, Patrick Fievet, Pierre Ronco, Catherine Johanet, P.A. Michel, Emmanuelle Plaisier, Laurent Mesnard, Johann Morelle, Emmanuel Esteve, Jean-Jacques Boffa |
| المساهمون: | UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, UCL - (SLuc) Service de médecine interne générale, Service de Néphrologie et Dialyses [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Cliniques Universitaires Saint-Luc [Bruxelles], Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Tenon [APHP], Service d'immunologie et hématologies biologiques [Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Sorbonne Université (SU)-CHU Saint-Antoine [APHP], Urgences néphrologiques et transplantation rénale [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'immunologie et hématologies biologiques [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) |
| المصدر: | Kidney international reports, Vol. 5, no. 3, p. 331-338 (2020) Kidney International Reports Kidney International Reports, Elsevier, 2020, 5 (3), pp.331-338. ⟨10.1016/j.ekir.2019.12.006⟩ Kidney International Reports, Vol 5, Iss 3, Pp 331-338 (2020) |
| بيانات النشر: | Elsevier, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Urinary system, PLA2R, 030232 urology & nephrology, Renal function, 030204 cardiovascular system & hematology, lcsh:RC870-923, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, rituximab, Membranous nephropathy, Clinical Research, Interquartile range, Internal medicine, medicine, CKD, ESKD, business.industry, membranous nephropathy, immunosuppressive treatment, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, lcsh:Diseases of the genitourinary system. Urology, medicine.disease, 3. Good health, Regimen, Nephrology, Rituximab, business, Nephrotic syndrome, medicine.drug, Kidney disease |
| الوصف: | Introduction Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membranous nephropathy. Whether its use is also appropriate in patients with an estimated glomerular filtration rate Graphical abstract |
| اللغة: | English |
| تدمد: | 2468-0249 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f93916d52202f453b67aec758c4c6db5Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f93916d52202f453b67aec758c4c6db5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 24680249 |
|---|